MX2021001397A - Sistema de nanoparticulas de dispersion mucoadhesiva y metodo de produccion del mismo. - Google Patents

Sistema de nanoparticulas de dispersion mucoadhesiva y metodo de produccion del mismo.

Info

Publication number
MX2021001397A
MX2021001397A MX2021001397A MX2021001397A MX2021001397A MX 2021001397 A MX2021001397 A MX 2021001397A MX 2021001397 A MX2021001397 A MX 2021001397A MX 2021001397 A MX2021001397 A MX 2021001397A MX 2021001397 A MX2021001397 A MX 2021001397A
Authority
MX
Mexico
Prior art keywords
nanoparticle system
dispersion nanoparticle
mucoadhesive dispersion
mucoadhesive
production
Prior art date
Application number
MX2021001397A
Other languages
English (en)
Inventor
Christo Tzachev Tzachev
Original Assignee
Lead Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Biotherapeutics Ltd filed Critical Lead Biotherapeutics Ltd
Publication of MX2021001397A publication Critical patent/MX2021001397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un sistema de nanopartículas de dispersión mucoadhesiva aplicable en farmacia, medicina y cosmética, especialmente por administración a superficies con depuración fisiológica intensiva tales como superficies nasales, pulmonares, oculares, bucales, de garganta, rectales, vaginales, etc., así como al método para la producción de tal sistema de nanopartículas de dispersión mucoadhesiva. La composición del sistema de nanopartículas de dispersión mucoadhesiva comprende un medio acuoso de hidroxipropilmetilcelulosa al 0.01 a 2.00% en peso y nanopartículas lipídicas sólidas dispersas (SLN) al 0.10 a 10% en peso para la liberación intracelular de sustancias activas. Las ventajas de la composición del sistema de nanopartículas de dispersión mucoadhesiva de SLN de la invención son una mayor eficacia y un efecto depo controlable para el transporte y suministro de sustancias activas.
MX2021001397A 2018-09-11 2018-09-11 Sistema de nanoparticulas de dispersion mucoadhesiva y metodo de produccion del mismo. MX2021001397A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/001073 WO2020053609A1 (en) 2018-09-11 2018-09-11 Mucoadhesive dispersion nanoparticle system and method for production the same

Publications (1)

Publication Number Publication Date
MX2021001397A true MX2021001397A (es) 2021-04-12

Family

ID=63857975

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001397A MX2021001397A (es) 2018-09-11 2018-09-11 Sistema de nanoparticulas de dispersion mucoadhesiva y metodo de produccion del mismo.

Country Status (15)

Country Link
US (1) US20210353553A1 (es)
EP (1) EP3820439B1 (es)
JP (1) JP7164700B2 (es)
BR (1) BR112021001674A2 (es)
CA (1) CA3110773C (es)
DK (1) DK3820439T3 (es)
ES (1) ES2901469T3 (es)
HR (1) HRP20211996T1 (es)
HU (1) HUE056959T2 (es)
IL (1) IL280371B (es)
LT (1) LT3820439T (es)
MX (1) MX2021001397A (es)
PL (1) PL3820439T3 (es)
SI (1) SI3820439T1 (es)
WO (1) WO2020053609A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603131A (en) 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EP1051155B1 (en) 1998-01-30 2002-06-26 Novartis Consumer Health S.A. Nasal solutions
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
ES2284398B2 (es) 2006-04-27 2008-12-16 Universidad Complutense De Madrid Formulacion de vesiculas liposomales en soluciones acuosas con caracteristicas de pelicula lagrimal.
WO2008105852A2 (en) 2006-10-26 2008-09-04 Creighton University Mucoadhesive nanoparticles for cancer treatment
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
US9321782B2 (en) 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
KR20140031227A (ko) * 2011-03-24 2014-03-12 레오 파마 에이/에스 지질 나노입자들 및 코르티코스테로이드 또는 비타민 ｄ 유도체를 포함하는 조성물
US9993439B2 (en) 2012-06-20 2018-06-12 University Of Waterloo Mucoadhesive nanoparticle delivery system
CA2912578A1 (en) 2013-06-20 2014-12-24 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
CN103784421B (zh) * 2014-02-27 2016-04-27 哈尔滨医科大学 载姜黄素和胡椒碱的固体脂质纳米粒及其制备方法
WO2015195708A1 (en) 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
JP2016034918A (ja) 2014-08-01 2016-03-17 静岡県公立大学法人 難水溶性抗酸化物質送達用組成物
WO2017075565A1 (en) 2015-10-30 2017-05-04 The Johns Hopkins University Mucus penetrating particles with high molecular weight and dense coatings
EP3386540A1 (en) 2015-12-08 2018-10-17 GlaxoSmithKline Biologicals S.A. Novel adjuvant formulations

Also Published As

Publication number Publication date
IL280371B (en) 2021-05-31
HUE056959T2 (hu) 2022-04-28
EP3820439A1 (en) 2021-05-19
LT3820439T (lt) 2022-01-10
SI3820439T1 (sl) 2022-02-28
EP3820439B1 (en) 2021-09-29
WO2020053609A1 (en) 2020-03-19
JP2022511223A (ja) 2022-01-31
DK3820439T3 (da) 2021-12-20
IL280371A (en) 2021-03-01
ES2901469T3 (es) 2022-03-22
JP7164700B2 (ja) 2022-11-01
CA3110773A1 (en) 2020-03-19
HRP20211996T1 (hr) 2022-04-01
CA3110773C (en) 2023-02-28
PL3820439T3 (pl) 2022-04-04
US20210353553A1 (en) 2021-11-18
BR112021001674A2 (pt) 2021-05-04

Similar Documents

Publication Publication Date Title
Khatoon et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting
Ghori et al. Nasal drug delivery systems: an overview
Milivojevic et al. Gellan gum in drug delivery applications
Loftsson et al. Topical drug delivery to the eye: dorzolamide
Akhter et al. Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system
Osmałek et al. Recent advances in polymer-based vaginal drug delivery systems
Luppi et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine
Romero et al. Development of cationic nanocrystals for ocular delivery
Pramanik et al. Connecting the dots in drug delivery: a tour d'horizon of chitosan-based nanocarriers system
JP2016535777A5 (es)
US20160346294A1 (en) Treatments for resistant acne
Mehra et al. Safety and toxicity of nanomaterials for ocular drug delivery applications
CL2009001856A1 (es) Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente.
MD3548091T2 (ro) Prepararea complexelor solide de ciclodextrină pentru livrarea ingredientelor farmaceutice active oftalmice
NZ725028A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
JP2013513612A5 (es)
GB0814302D0 (en) Compounds and methods
Esteban-Pérez et al. Gelatin nanoparticles-HPMC hybrid system for effective ocular topical administration of antihypertensive agents
Zeng et al. Degradable nanoparticles restore lysosomal pH and autophagic flux in lipotoxic pancreatic beta cells
TW201400142A (zh) 有機化合物奈米粉末、其製造方法及懸浮液
FI3295943T3 (fi) Vesipitoinen suspensioaine, joka käsittää glukokortikosteroidinanopartikkeleita
Menon et al. Cytotoxic effects of phosphonate-functionalized mesoporous silica nanoparticles
Zaid Alkilani et al. Formulation and evaluation of azithromycin-loaded niosomal gel: optimization, in vitro studies, rheological characterization, and cytotoxicity study
El-Menshawe A novel approach to topical acetazolamide/PEG 400 ocular niosomes
MX2021001397A (es) Sistema de nanoparticulas de dispersion mucoadhesiva y metodo de produccion del mismo.